What's in Pontificia Universidade Catolica de Sao Paulo's pipeline?

Pontificia Universidade Catolica de Sao Paulo has 11 drugs in our index: 11 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Pontificia Universidade Catolica de Sao Paulo's portfolio?

Top competitors by shared drug class: Eisai Co., Ltd., Eisai Inc., Icure Pharmaceutical Inc., Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Ludwig-Maximilians - University of Munich.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pontificia-universidade-catolica-de-sao-paulo.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Pontificia Universidade Catolica de Sao Paulo — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pontificia Universidade Catolica de Sao Paulo pipeline: 11 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Pneumoperitoneum pressure 10 mmHg	Pneumoperitoneum pressure 10 mmHg	marketed	N/A (Procedural Technique)	Abdominal cavity	Infectious Disease
TIVA - Neostigmine 30	TIVA - Neostigmine 30	marketed
Sevoflurane - Neostigmine 50	Sevoflurane - Neostigmine 50	marketed
TIVA - Neostigmine 70	TIVA - Neostigmine 70	marketed	Acetylcholinesterase inhibitor	Acetylcholinesterase	Neurology
Pneumoperitoneum pressure 14 mmHg	Pneumoperitoneum pressure 14 mmHg	marketed
Reversal of moderate neuromuscular blockade	Reversal of moderate neuromuscular blockade	marketed
Reversal of superficial neuromuscular blockade	Reversal of superficial neuromuscular blockade	marketed	Neuromuscular blockade reversal agent	Acetylcholinesterase or neuromuscular blocking agents (depending on specific agent)	Anesthesiology
Two-step reversal	Two-step reversal	marketed			Toxicology
Sevoflurane - Neostigmine 70	Sevoflurane - Neostigmine 70	marketed	Volatile anesthetic with cholinesterase inhibitor	GABA receptors (sevoflurane); acetylcholinesterase (neostigmine)	Anesthesiology
Sevoflurane - Neostigmine 30	Sevoflurane - Neostigmine 30	marketed	Volatile anesthetic with cholinesterase inhibitor		Anesthesiology
TIVA - Neostigmine 50	TIVA - Neostigmine 50	marketed	Cholinesterase inhibitor	Acetylcholinesterase	Neurology

Therapeutic area mix

Anesthesiology · 3
Neurology · 2
Infectious Disease · 1
Toxicology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eisai Co., Ltd. · 1 shared drug class
Eisai Inc. · 1 shared drug class
Icure Pharmaceutical Inc. · 1 shared drug class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 shared drug class
Ludwig-Maximilians - University of Munich · 1 shared drug class
Merck Sharp & Dohme LLC · 1 shared drug class
Neurognostics · 1 shared drug class
Chung-Ang University Hosptial, Chung-Ang University College of Medicine · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pontificia Universidade Catolica de Sao Paulo:

Cite this brief

Drug Landscape (2026). Pontificia Universidade Catolica de Sao Paulo — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pontificia-universidade-catolica-de-sao-paulo. Accessed 2026-05-17.